The copy number analyses in the adjuvant setting, except for the ER-negative LNN analysis, had sufficient power to conclude that there is no or only a marginal prognostic effect of APOBEC3B copy numbers in breast cancer patients (Fig 3). Here, APOBEC3B is linked to breast carcinoma.